Literature DB >> 19506813

Targeted delivery of bleomycin to the brain using photo-chemical internalization of Clostridium perfringens epsilon prototoxin.

Henry Hirschberg1,2, Michelle J Zhang3, H Michael Gach4, Francisco A Uzal5, Qian Peng6, Chung-Ho Sun7, David Chighvinadze3, Steen J Madsen3.   

Abstract

Cells infiltrating into normal brain from malignant brain tumors are protected by the blood brain barrier (BBB) which prevents the delivery and limits the effects of anti-tumor agents. We have evaluated the ability of photochemical internalization (PCI) to limit the effects of an agent known to broadly open the BBB to a target region of the brain. The PCI-based relocation and activation of macromolecules into the cell cytosol has the advantage of minimal side effects since the effect is localized to the area exposed to light, allowing the access of chemotherapeutic agents only to these regions. Non tumor bearing inbred Fisher rats were treated with photosensitizer, and a nontoxic intraperitoneal dose of Clostridium perfringens epsilon prototoxin (ETXp) followed by light exposure. Post-contrast T(1) MRI scans were used to monitor the degree BBB disruption. F98 tumor cells were implanted into the brains of other animals that were subsequently treated 24 h later with ETXp-PCI BBB opening followed by the i.p. administration of bleomycin (BLM). PCI delivery of ETXp at low fluence levels demonstrated significant MRI enhancement. No effect on the BBB was observed if photosensitizer and light was given in the absence ETXp. The survival of animals implanted with F98 tumor cells was significantly extended following ETXp-PCI BBB opening and BLM therapy compared to controls. PCI delivered ETXp was effective in opening the BBB in a limited region of the brain. ETXp-PCI mediated BBB opening clearly increased the efficacy of BLM therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506813      PMCID: PMC2773371          DOI: 10.1007/s11060-009-9930-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  41 in total

1.  Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors.

Authors:  N D Doolittle; M E Miner; W A Hall; T Siegal; E Jerome; E Osztie; L D McAllister; J S Bubalo; D F Kraemer; D Fortin; R Nixon; L L Muldoon; E A Neuwelt
Journal:  Cancer       Date:  2000-02-01       Impact factor: 6.860

2.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

Authors:  R W Rand; R J Kreitman; N Patronas; F Varricchio; I Pastan; R K Puri
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

3.  Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin.

Authors:  P K Selbo; G Sivam; O Fodstad; K Sandvig; K Berg
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

4.  5-Aminolevulinic acid-based photochemical internalization of the immunotoxin MOC31-gelonin generates synergistic cytotoxic effects in vitro.

Authors:  P K Selbo; O Kaalhus; G Sivam; K Berg
Journal:  Photochem Photobiol       Date:  2001-08       Impact factor: 3.421

5.  Development of a novel indwelling balloon applicator for optimizing light delivery in photodynamic therapy.

Authors:  S J Madsen; C H Sun; B J Tromberg; H Hirschberg
Journal:  Lasers Surg Med       Date:  2001       Impact factor: 4.025

Review 6.  Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation.

Authors:  Rolf F Barth; Weilian Yang; Jeffrey A Coderre
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

7.  Disruption of the blood-brain barrier following ALA-mediated photodynamic therapy.

Authors:  Henry Hirschberg; Francisco A Uzal; David Chighvinadze; Michelle J Zhang; Qian Peng; Steen J Madsen
Journal:  Lasers Surg Med       Date:  2008-10       Impact factor: 4.025

Review 8.  Cost of migration: invasion of malignant gliomas and implications for treatment.

Authors:  A Giese; R Bjerkvig; M E Berens; M Westphal
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

9.  Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.

Authors:  John H Sampson; Gamal Akabani; Gary E Archer; Darell D Bigner; Mitchel S Berger; Allan H Friedman; Henry S Friedman; James E Herndon; Sandeep Kunwar; Steve Marcus; Roger E McLendon; Alison Paolino; Kara Penne; James Provenzale; Jennifer Quinn; David A Reardon; Jeremy Rich; Timothy Stenzel; Sandra Tourt-Uhlig; Carol Wikstrand; Terence Wong; Roger Williams; Fan Yuan; Michael R Zalutsky; Ira Pastan
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

10.  Photochemical disruption of endocytic vesicles before delivery of drugs: a new strategy for cancer therapy.

Authors:  L Prasmickaite; A Høgset; P K Selbo; B Ø Engesaeter; M Hellum; K Berg
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

View more
  12 in total

1.  Photochemical internalization-mediated nonviral gene transfection: polyamine core-shell nanoparticles as gene carrier.

Authors:  Genesis Zamora; Frederick Wang; Chung-Ho Sun; Anthony Trinidad; Young Jik Kwon; Soo Kyung Cho; Kristian Berg; Steen J Madsen; Henry Hirschberg
Journal:  J Biomed Opt       Date:  2014       Impact factor: 3.170

2.  Increased sensitivity of glioma cells to 5-fluorocytosine following photo-chemical internalization enhanced nonviral transfection of the cytosine deaminase suicide gene.

Authors:  Frederick Wang; Genesis Zamora; Chung-Ho Sun; Anthony Trinidad; Changho Chun; Young Jik Kwon; Kristian Berg; Steen J Madsen; Henry Hirschberg
Journal:  J Neurooncol       Date:  2014-03-08       Impact factor: 4.130

3.  Photochemical internalization of bleomycin for glioma treatment.

Authors:  Marlon S Mathews; Joseph W Blickenstaff; En-Chung Shih; Genesis Zamora; Van Vo; Chung-Ho Sun; Henry Hirschberg; Steen J Madsen
Journal:  J Biomed Opt       Date:  2012-05       Impact factor: 3.170

4.  Enhancing the effects of chemotherapy by combined macrophage-mediated photothermal therapy (PTT) and photochemical internalization (PCI).

Authors:  Rohit Kumar Nair; Catherine Christie; David Ju; Diane Shin; Aftin Pomeroy; Kristian Berg; Qian Peng; Henry Hirschberg
Journal:  Lasers Med Sci       Date:  2018-05-26       Impact factor: 3.161

5.  Identification of amino acids important for binding of Clostridium perfringens epsilon toxin to host cells and to HAVCR1.

Authors:  Susan E Ivie; Mark S McClain
Journal:  Biochemistry       Date:  2012-09-12       Impact factor: 3.162

Review 6.  Site-specific opening of the blood-brain barrier.

Authors:  Steen J Madsen; Henry Hirschberg
Journal:  J Biophotonics       Date:  2010-06       Impact factor: 3.207

7.  Increased nanoparticle-loaded exogenous macrophage migration into the brain following PDT-induced blood-brain barrier disruption.

Authors:  Steen J Madsen; H Michael Gach; Seok Jin Hong; Francisco A Uzal; Qian Peng; Henry Hirschberg
Journal:  Lasers Surg Med       Date:  2013-08-30       Impact factor: 4.025

8.  7.0-T magnetic resonance imaging characterization of acute blood-brain-barrier disruption achieved with intracranial irreversible electroporation.

Authors:  Paulo A Garcia; John H Rossmeisl; John L Robertson; John D Olson; Annette J Johnson; Thomas L Ellis; Rafael V Davalos
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

Review 9.  Enhancing the efficacy of cytotoxic agents for cancer therapy using photochemical internalisation.

Authors:  Alejandra Martinez de Pinillos Bayona; Caroline M Moore; Marilena Loizidou; Alexander J MacRobert; Josephine H Woodhams
Journal:  Int J Cancer       Date:  2015-03-23       Impact factor: 7.396

10.  Clostridium perfringens epsilon toxin mutant Y30A-Y196A as a recombinant vaccine candidate against enterotoxemia.

Authors:  Monika Bokori-Brown; Charlotte A Hall; Charlotte Vance; Sérgio P Fernandes da Costa; Christos G Savva; Claire E Naylor; Ambrose R Cole; Ajit K Basak; David S Moss; Richard W Titball
Journal:  Vaccine       Date:  2014-04-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.